arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Apimeds Pharmaceuticals US, Inc.

APUS

$2.67 ▼ -0.16 (-5.64%) at close

12 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Neutral

auto_awesome

Analytical Summary

Apimeds Pharmaceuticals US, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $4.6M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -4.7% ↗

FCF / Share $-3.31 ↘

Trailing P/E —

Price / Book 0.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

12-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-35.06M

↓ -8612.8% —

FCF / Share Free cash flow per share

$-3.31

↓ -2370.3% —

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	-4426.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-4420.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-100.0% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-250.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-333.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-25.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-8612.8% Weak ↓ Weak Declining Year-over-year change in net income	-8612.8% Weak ↓ Weak Declining Year-over-year change in net income	-270.7% Weak ↓ Weak Declining Year-over-year change in net income	-35.7% Weak → Weak Stable Year-over-year change in net income	-35.7% Weak Weak Year-over-year change in net income	-35.7% Weak Weak Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	—	-5109.8% Weak Weak Year-over-year change in free cash flow	—	-488.5% Weak Weak Year-over-year change in free cash flow	—	92.3% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	0.16x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.06x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	3.32x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	4.35x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	—	0.05x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.32x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.63x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.62x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-4.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-7.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-3.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-17.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	16.4% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	16.0% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	22.6% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	47.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	81.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-4.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-8.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-4.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-19.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-25.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-140.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-2110.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	-32.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-320%)	-27.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-285%)	-0.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-105%)	-4.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-133%)	-4.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-128%)	22.9% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+52%)	22.9% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+53%)	28.3% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+89%)	41.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+177%)	112.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+647%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Interest Coverage (x)	—	-1452.93x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	-864.34x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	—
Net Debt (USD)	$-278.37K	$-979.53K	$-1.64M	$-6.99M	$-8.74M	$-250.34K	$-3.46K	—	—	—	$-410.48K	—

📊 What does each share earn? 5 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Basic EPS, GAAP (USD)	$-11.77	$-2.26	$-0.08	$-0.14	$-0.26	$-0.05	$-0.04	$-0.04	$-0.06	$-0.04	—	—
Free Cash Flow per Share (USD)	$-3.31	$-0.13	—	$-0.14	—	$-0.00	—	$-0.02	$-0.02	$-0.03	—	—
Book Value per Share (USD)	$70.54	$10.06	$12.19	$0.65	$0.77	$-0.22	$-0.17	$-0.13	$-0.09	$-0.03	$0.00	—
Tangible Book Value per Share (USD)	$70.54	$10.06	$12.19	$0.65	$0.77	$-0.22	$-0.17	$-0.13	$-0.09	$-0.03	$0.00	—
Basic Weighted Avg Shares (shares)	1.71M	15.51M	—	12.58M	10.37M	7.90M	—	7.90M	7.90M	7.90M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$-10.39M	$-1.43M	$3.28M	$8.00M	$9.54M	$-1.51M	$-1.01M	—	—	—	$298.76K	—
Total Equity (USD)	$106.45M	$126.52M	$153.35M	$8.16M	$9.74M	$-1.76M	$-1.36M	$-1.05M	$-713.97K	$-264.60K	$31.87K	$-713.61K

📋 What is driving earnings? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Depreciation Expense (USD)	$4.66K	$20.04K	$3.98K	$1.49K	—	—	—	—	—	—	—	—
Net Income, GAAP (USD)	$-35.06M	$-35.06M	$-1.16M	$-402.40K	$-402.40K	$-402.40K	$-311.63K	$-296.47K	$-296.47K	$-296.47K	—	—
Operating Cash Flow (USD)	$-5.67M	$-2.07M	$-3.82M	$-1.73M	—	$-20.31K	$-99.62K	$-186.75K	$-184.06K	$-263.10K	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 4 years · 12 quarters

Apimeds Pharmaceuticals US, Inc.

Analytical Summary

12-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare APUS with peers